A kind of preparation method of pharmaceutical grade benzethonium chloride

By using potassium iodide, sodium iodide and polyethylene glycol catalyst system and Buchwald-Hartwig coupling reaction in benzethonium synthesis, combined with molecular distillation and low-temperature quaternization, safety hazards and quality problems of high-temperature and high-pressure processes are solved. It has achieved efficient and high-quality pharmaceutical grade benzethonium chloride preparation, which meets strict pharmacopoeia standards.

CN117384050BActive Publication Date: 2024-11-05GAOYOU CITY ORGANIC CHEM FACOTRY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202311323346.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-10-12
Publication Date
2024-11-05
Estimated Expiration
2043-10-12

AI Technical Summary

Technical Problem

The existing benzethonium chloride synthesis process requires high temperature and high pressure, which poses safety risks and poor product quality, making it difficult to meet the quality standards of the pharmaceutical grade.

Method used

The chlorine replacement reaction is carried out using a catalyst system of potassium iodide, sodium iodide and polyethylene glycol. Combined with the Buchwald-Hartwig coupling reaction, the C-N coupling reaction is carried out in the presence of palladium catalysis and alkali, which reduces the reaction temperature and removes harmful impurities. Molecular distillation treatment and low-temperature quaternization reaction form pharmaceutical grade benzethonium chloride.

Benefits of technology

It achieves efficient synthesis at normal pressure temperature, significantly improves product purity and quality, meets medical-grade standards, and is better than the requirements of the US and European pharmacopoeia.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117384050B_ABST
    Figure CN117384050B_ABST
Patent Text Reader

Abstract

The invention discloses a method for preparing pharmaceutical-grade benzethonium chloride, which uses a salt of aryl polyoxyalkyl chloride and dimethylamine to carry out C-N coupling reaction, and by introducing a palladium catalyst or a catalyst of iodized salt and polyethylene glycol, amination reaction is achieved at normal pressure and mildly; after molecular distillation treatment, harmful impurities are removed to obtain compound 3; then compound 3 and benzyl chloride are subjected to quaternization reaction in a solvent, and a benzethonium chloride product that meets the standard of bulk drug can be obtained. The present invention improves product quality in terms of purity, impurities, residual solvents and chromaticity, and the product index control is more stringent, leading the standards of domestic and foreign peers and customers, and is better than the USP36 standard of the United States Pharmacopoeia and the EP10.0 standard of the European Pharmacopoeia.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a preparation method of pharmaceutical-grade benzethonium chloride, and belongs to the technical field of medicines. Background Art

[0002] Benzethonium chloride, also known as benzyl dimethyl [2-[2-[4-(1,1,3,3-tetramethylbutyl) phenoxy] ethoxy] ethyl] ammonium chloride, CAS registration number is 121-54-0. It is a flaky crystal with a melting point of 164-166°C. It is easily soluble in water to form a foamy soapy solution. It is soluble in ethanol, acetone, and chloroform.

[0003] The chemical structure of benzethonium chloride is as follows:

[0004]

[0005] Benzethonium chloride is also used as a bactericidal and antibacterial agent in the medical and health field. For example, it has been widely used as an antibacterial component of eye drops or as an antibacterial component of injection solutions in Western countries. This product is included in the FDA "Inactive Ingredients Guide" (intramuscular preparations, intravenous preparations, ophthalmic preparations and otic preparations).

[0006] In the field of sodium heparin, the annual demand for this product reaches 500 tons, which is mainly used for purifying sodium heparin, or for the production of low molecular weight sodium heparin and enoxaparin, as a key starting material for the synthesis of enoxaparin, to prevent deep vein thrombosis and pulmonary embolism, treat existing venous thrombosis, prevent the formation of thrombus in extracorporeal circulation during hemodialysis, and treat unstable angina and non-Q wave myocardial infarction. Benzethonium chloride can also be used as a wetting agent, solubilizer and external disinfectant. In cosmetics such as deodorants, solutions with a concentration of benzethonium chloride greater than 0.5% w / v can also be used as antibacterial agents.

[0007] The synthetic route of benzethonium chloride in the prior art has several as follows:

[0008] Beijing Sangpu Biochemistry Co., Ltd. disclosed the following technical scheme in U.S. Patent US2014187819 (A1): 1) Phenol reacts with dihalogenated polyalkylene ether under the action of a phase transfer catalyst to obtain an aryl polyoxyalkyl halide; 2) An aryl polyoxyalkyl halide reacts with an aminating agent under the action of a phase transfer catalyst to obtain an aryl polyoxyalkyl amine; 3) An aryl polyoxyalkyl amine reacts with an alkylating agent to obtain an aryl polyoxyalkyl quaternary ammonium compound.

[0009] The reaction equation of this technical route is as follows:

[0010]

[0011] The above technical solution uses a large amount of phase transfer catalyst benzyltriethylammonium chloride, the reaction temperature is about 160° C., and the reaction pressure reaches about 8-10 kg, which has strict requirements on equipment and is not conducive to the expansion of the production workshop.

[0012] Clariant Manufacturing (Germany) Co., Ltd. disclosed the quaternization reaction of aryl polyoxyalkyl halides and dimethylbenzylamine in U.S. Patent US2003114533 (A1). Although the invention claims to simplify the preparation process, the actual application also involves the preparation of the raw material aryl polyoxyalkyl halide, and the collection and purification of the product quaternary ammonium substances are too complicated. Since the halogen activity of aryl polyoxyalkyl halides is also very low, the reaction with benzyl dimethylamine has long high-temperature reaction time and temperature and pressure resistance problems of the reaction equipment. The most important thing is that the high-temperature reaction leads to poor product quality, which is not the best commercial production route. The reaction formula of this technical route is as follows:

[0013]

[0014] Chinese patents CN113372227 (A) and CN109651177 (A) respectively disclose a method for preparing benzethonium chloride, wherein p-tert-octylphenol is added with ethylene dichloride for a one-step reaction, then mixed with dimethylethanolamine for a two-step reaction, and finally benzyl chloride is added for a three-step reaction to obtain a product, and the reaction equation is as follows:

[0015]

[0016] However, the reaction temperature in this preparation method is also relatively high, and there are hidden dangers in high temperature and high pressure environments. Benzethonium chloride is a quaternary ammonium compound, which is used as an antibacterial agent in pharmaceutical preparations. It can be used as an antibacterial agent for injection, ophthalmic preparations and ear preparations. Therefore, the synthesis of benzethonium chloride should try not to involve the use of 1,2-dichloroethane, a type of solvent known to be carcinogenic and harmful to humans and the environment, so this route is not suitable for production.

[0017] India's Dishman disclosed in its patent EP1892235 (A) a method of synthesizing 4-tert-octylphenol, chloroethanol and (β-chloroethyl) dimethylamine as raw materials in three steps, all of which are reactions under normal pressure. The reaction equation is as follows:

[0018]

[0019] 2-Dimethylaminoethyl chloride hydrochloride has a genotoxic warning structure of halogenated hydrocarbons, so it is necessary to control such impurities, which affects the safety of benzethonium chloride products. Chloroethanol is a highly toxic drug. According to relevant laws, regulations and policies in China, the production, sale, use or possession of this product is prohibited. Therefore, the method of this patent is not suitable for commercial production.

[0020] In summary, the current production process requires high temperature and pressure, which poses a hidden danger to production safety. It is necessary to improve the process and reduce the harsh conditions of the reaction to obtain high-quality pharmaceutical-grade benzethonium chloride products. Summary of the invention

[0021] In order to overcome the above technical problems, the present invention provides a method for preparing pharmaceutical grade benzethonium chloride, and the reaction process is as follows:

[0022] S1:

[0023]

[0024] , wherein HX is hydrochloric acid, hydrobromic acid, sulfuric acid or hydroiodic acid;

[0025] S2:

[0026]

[0027] In view of the shortcomings of the existing synthesis methods, the source and theoretical basis of the innovative technical method of the present invention are described in detail below.

[0028] S1:

[0029] At present, the technical solution in U.S. Patent US2014187819 (A1) is generally adopted in production at home and abroad. Aryl polyoxyalkyl halides react with aminating agents under the action of phase transfer catalysts to obtain aromatic polyoxyalkyl amides. Even if a large amount of phase transfer catalysts are used, the reaction temperature used in the patent is about 160°C, and the reaction pressure reaches about 8-10 kg.

[0030] Clariant Manufacturing (Germany) AG uses a quaternization reaction of aromatic polyoxyalkyl halides and dimethylbenzylamine in U.S. Patent US2003114533 (A1), with a reaction temperature of 120°C and a reaction pressure of about 2 kg. The quaternary ammonium product obtained in this patent has poor quality and requires an overly complicated purification operation to produce a qualified product.

[0031] Due to the low reactivity of the chlorine atoms in the aromatic polyoxyalkyl halides, almost all manufacturers currently use aqueous dimethylamine solution for amination reaction, resulting in the current production process requiring high temperature and pressure, which poses a hidden danger to production safety. It is necessary to improve the process and reduce the harsh conditions of the reaction, which is the key technical problem that the present invention needs to solve.

[0032] From the perspective of organic synthesis theory, a catalyst system including potassium iodide, sodium iodide and polyethylene glycol is used to carry out a nucleophilic substitution reaction of chlorine replacement, in which iodide ions replace chloride ions. The leaving ability of iodide ions is much greater than that of chloride ions. After iodide ions leave, they can circulate and act on the remaining reaction system, thereby greatly increasing the reaction rate and reducing the reaction temperature.

[0033] In addition, the Buchwald-Hartwig coupling reaction is an important method for synthesizing aromatic amines. The reaction is a cross-coupling reaction of amines and aromatic halides in the presence of palladium catalyst and base to produce a CN bond and generate an N-arylated product of the amine.

[0034] The present invention accordingly uses a salt of aryl polyoxyalkyl chloride and dimethylamine to carry out a CN coupling reaction, and by introducing a palladium catalyst or an iodide salt and a polyethylene glycol catalyst, amination reaction can be mildly achieved at normal pressure, thereby forming the preparation method of step 1 of the present invention.

[0035] S2:

[0036] Since benzethonium chloride is used for mucosal disinfection, eye drops and mildew prevention of powder products, it must be extremely low irritation. The harmful impurities, such as residual solvents, benzyl chloride, and β, β'-dichlorodiethyl ether, etc., are not effectively controlled in the existing technology, resulting in the product failing to meet the quality requirements of pharmaceutical grade.

[0037] According to the ICHQ3 guidelines of the International Council for Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, the quality specifications of benzethonium chloride of most manufacturers do not meet the requirements of pharmaceutical grade.

[0038] For example: The product indicators of a domestic company are as follows, but according to the guiding principles of ICHQ3 for raw materials, the indicators lack control standards for the limits of harmful impurities.

[0039]

[0040] The currently reported method for purifying tert-octylphenoxyethoxyethyldimethylamine is through a vacuum distillation method. However, during the distillation process, the product is exposed to high temperature for a long time, which will lead to degradation and polymerization of the product, which not only reduces the yield, but also may cause impurities in the product, resulting in unqualified products.

[0041] The present invention has found that the 4-tert-octylphenoxyethoxyethyldimethylamine prepared in the first step is subjected to molecular distillation to remove harmful impurities, and then reacts with benzyl chloride in a solvent at low temperature for quaternization, thereby forming the current industry-leading preparation process for step 2.

[0042] At the same time, the present invention draws on the product indicators of domestic and foreign counterparts and formulates an enterprise standard for benzethonium chloride products with manufacturing characteristics based on the guiding principles of ICHQ3, which is superior to the United States Pharmacopoeia USP36 standard and the European Pharmacopoeia EP10.0 standard.

[0043] The beneficial result is that the present invention improves the product quality in terms of purity, impurities, residual solvents and chromaticity, and the product index control is more stringent, leading the standards of domestic and foreign peers and customers.

[0044]

[0045] The preparation method of the above-mentioned pharmaceutical grade benzethonium chloride comprises the following steps:

[0046] S1-1: Preparation of compound 3

[0047] Into the reaction kettle, add 4-tert-octylphenoxyethoxyethyl chloride 2, dimethylamine salt and catalyst under nitrogen protection, heat up to react, maintain for 2-5 hours, and control by HPLC detection: when the residual amount of 4-tert-octylphenoxyethoxyethyl chloride 2 is controlled to be ≤3.0%, the reaction is completed; after the reactants are stirred for reaction, the temperature is lowered to below 35°C, ethyl acetate is added, and the reaction solution is allowed to stand and separate to obtain an organic layer.

[0048] Furthermore, the dimethylamine salt in step S1-1 is dimethylamine hydrochloride, dimethylamine hydrobromide, dimethylamine sulfate and dimethylamine hydroiodide, preferably dimethylamine hydrochloride.

[0049] Furthermore, the catalyst in step S1-1 is at least one of lithium chloride, lithium bromide, potassium bromide, sodium bromide, cuprous bromide, sodium iodide, potassium iodide, cuprous iodide and palladium catalyst; preferably sodium iodide and palladium catalyst.

[0050] Furthermore, the palladium catalyst is Pd(OAc)2, Pd2(dba)3, PdCl2(dppf), PdCl2(PPh3)2, PdCl2(PCy)2, PdCl2, PdCl2(CH3CN)2, etc.; preferably PdCl2(dppf).

[0051] S1-2: Purification of crude product

[0052] The organic layer was decompressed using an oil pump, the vacuum degree of the distillation system was controlled at 0.01-1.0 mbar, the oil bath temperature was 160-180°C, the speed of the scraper was 200-300 rpm, the sample was continuously injected, the injection speed was controlled, and compound 3 was obtained by molecular distillation.

[0053] Furthermore, the distillation method in step S1-2 is reduced pressure distillation, high vacuum distillation, molecular distillation; preferably molecular distillation.

[0054] Furthermore, the absolute pressure during molecular distillation in step S1-2 is 0.005MPa-0.01MPa.

[0055] S2-1: Preparation of Compound 1

[0056] Pre-treatment of compound 3: Add compound 3 and solvent into the reactor under nitrogen protection, stir and heat to 30-50°C, add activated carbon for decolorization for the specified time, and filter through a precision filter with a pore size of less than 45 microns to step S2-2 for reaction.

[0057] Furthermore, the solvent in step S2-1 is ethyl acetate, isopropyl acetate, acetonitrile, acetone or methyl isobutyl ketone; preferably ethyl acetate.

[0058] S2-2: Preparation of Compound 1

[0059] Into the reactor, under nitrogen protection, add the solution of compound 3 treated in step S2-1, then draw benzyl chloride through a precision filter, stir and heat to 40-60°C for reaction, keep the reaction for the specified time of the process, no need to take samples for central control, and end the reaction. Filter the reaction solution, add ethyl acetate to the obtained solid, stir and wash, and dry the obtained white solid under reduced pressure to obtain compound 1.

[0060] Furthermore, the reaction temperature in step S2-2 is 20-150°C; preferably 40-60°C.

[0061] Beneficial effects of the present invention:

[0062] 1. The corresponding aryl polyoxyalkyl chloride of the present invention and the salt of dimethylamine are subjected to CN coupling reaction, and amination reaction is mildly achieved at normal pressure by introducing a palladium catalyst or an iodide salt and a polyethylene glycol catalyst; harmful impurities are removed after molecular distillation treatment to obtain tert-octylphenoxyethoxyethyldimethylamine; and then quaternization reaction is carried out with benzyl chloride in a solvent to obtain a benzethonium chloride product that meets the standards for bulk drugs.

[0063] 2. The present invention has formulated relevant benzethonium chloride product enterprise standards based on reference to domestic and foreign counterparts' product indicators, which are superior to the United States Pharmacopoeia USP36 standard and the European Pharmacopoeia EP10.0 standard. BRIEF DESCRIPTION OF THE DRAWINGS

[0064] Figure 1 This is the HPLC spectrum of the purity detection of S2 compound 1 in Example 1. DETAILED DESCRIPTION

[0065] The following examples will help researchers understand the key points of the preparation technology of the present invention, but they cannot limit the content of the present invention.

[0066] Example 1

[0067] The present embodiment provides a method for preparing pharmaceutical grade benzethonium chloride, comprising the following steps:

[0068] S1: Synthesis of compound 3

[0069] Into the reactor, 48.0g of tert-octylphenoxyethoxyethyl chloride 2, 88.0g of dimethylamine hydrochloride, 2.5g of sodium iodide and 0.05g of PdCl2 (dppf) were added under nitrogen protection, the temperature was raised to 70-80°C for reaction, and the reaction was maintained for 5h. When the residual amount of tert-octylphenoxyethoxyethyl chloride 2 was controlled to be ≤3.0%, the reaction was completed; after the reactants were stirred for reaction, the temperature was lowered to below 35°C, 50.0g of ethyl acetate was added, and the reaction solution was allowed to stand for stratification to obtain an organic layer; the organic layer was decompressed using an oil pump, the vacuum degree of the distillation system was controlled to be 0.01-1.0mbar, the oil bath temperature was 160-180°C, the scraper speed was 200-300 rpm, the material injection speed was 5-10mL / min, and molecular distillation was performed to obtain 42.4g of colorless transparent liquid compound 3, with a yield of 86.0%, a GC purity of 99.52%, and unknown impurities less than 0.3%.

[0070] S2: Synthesis of compound 1

[0071] S2-1: Pre-treatment of compound 3

[0072] Into the reactor, add 300.0g of tert-octylphenoxyethoxyethyldimethylamine 3 and 900.0g of ethyl acetate under nitrogen protection, stir and heat to between 30-50°C, add 20.0g of needle-grade 767 charcoal for decolorization and adsorption for the specified time of the process, pass through a precision filter press with a pore size of less than 45 microns, filter to step S2-2 for reaction.

[0073] S2-2: Add the p-tert-octylphenoxyethoxyethyldimethylamine 3 solution of S2-1 into the reactor under nitrogen protection, then draw in 121.0g of benzyl chloride through a precision filter, stir and heat to 40-60°C for reaction. Keep the reaction for the specified time of the process, no need to take samples for central control, and terminate the reaction. Cool the reaction solution to 10-20°C and filter, add 300.0g of ethyl acetate to the obtained solid, stir and wash, vacuum dry the filter cake under -0.098MPa and 35°C, and then crush the filter cake to obtain the benzethonium chloride product. 365.9g of compound 1 was obtained, with a yield of 87.5% and an HPLC purity of 99.9% (such as Figure 1As shown in the figure, each impurity is less than 0.05%. After full inspection, it meets the internal quality control index of benzethonium chloride.

[0074] On the basis of keeping other substances unchanged, by changing different dimethylamine salts, the data listed in Table 1 below are obtained:

[0075] Experiment number Dimethylamine S1 product yield (%) Purity of product in step S1 (%) 1 Dimethylamine sulfate 83.5 97.8 2 Dimethylamino hydroiodide 84.2 98.2 3 Dimethylamine hydrobromide 82.6 98.5

[0076] On the basis of keeping other substances unchanged, changing the catalyst, we get the data listed in Table 2 below:

[0077]

[0078] Selection of product purification method in step S1:

[0079] On the basis of keeping other substances unchanged, the inventors compared different distillation methods and obtained the data listed in Table 3 below:

[0080]

[0081]

[0082] Example 2

[0083] The present embodiment provides a method for preparing pharmaceutical grade benzethonium chloride, comprising the following steps:

[0084] S1: Synthesis of compound 3

[0085] Into the reactor, add 240.0Kg of tert-octylphenoxyethoxyethyl chloride 2, 220Kg of dimethylamine hydrochloride, 1.5Kg of sodium iodide and 0.05Kg of PdCl2 (dppf), heat to 70-80℃ for reaction, maintain for 5h, control the residual amount of tert-octylphenoxyethoxyethyl chloride 2 to be ≤3.0%, the reaction is completed; after the reaction is completed by stirring the reactants, cool to below 35℃, add 100.0Kg of ethyl acetate, let the reaction solution stand for stratification to obtain an organic layer; use an oil pump to reduce the pressure of the organic layer, control the vacuum degree of the distillation system to 0.01-1.0mbar, the oil bath temperature to 160-180℃, the scraper speed to 200-300 rpm, the material injection speed to 50-60L / h, and molecular distillation to obtain 213.5Kg of colorless transparent liquid compound 3, with a yield of 86.37%, GC purity of 98.62%, and unknown impurities less than 0.3%.

[0086] S2: Synthesis of compound 1

[0087] S2-1: Decolorization and adsorption treatment of compound 3

[0088] Into the reactor, add 150Kg of tert-octylphenoxyethoxyethyldimethylamine 3 and 600.0Kg of ethyl acetate under nitrogen protection, stir and heat to between 30-50°C, add 20.0Kg of 767 type injection activated carbon for needles for decolorization and adsorption to the specified time of the process, and filter through a precision filter with a pore size of less than 45 microns to the S2-2 step for reaction.

[0089] S2-2: Add the p-tert-octylphenoxyethoxyethyldimethylamine 3 solution of S2-1 to the reactor under nitrogen protection, then draw in 121.0Kg of benzyl chloride through a precision filter, stir and heat to 40-60°C for reaction. Keep the reaction to the specified time of the process, no need to take samples for central control, and end the reaction. The reaction solution is cooled to 10-20°C for filtration, and 300.0Kg of ethyl acetate is added to the obtained solid for stirring and washing. The obtained solid is vacuum dried at -0.098MPa and 45°C, and the filter cake is crushed to be the benzethonium chloride product. 187.8Kg of compound 1 is obtained, with a yield of 89.8%, an HPLC purity of 99.9%, and a single impurity of less than 0.03%. After full inspection, it meets the quality control indicators of benzethonium chloride.

[0090] Comparative Example 1

[0091] This comparative example repeats Example 1 of U.S. Patent US2014187819 (A1) of Beijing Sangpu Biochemical Co., Ltd.

[0092] In a 1L sealed reactor, add 144.6g of tert-octylphenoxyethoxyethyl chloride, 11.4g of benzyltriethylammonium chloride, and 135.3g of 33% dimethylamine aqueous solution, seal it, heat it to 160°C, stir and react for 8h, and the conversion rate of tert-octylphenoxyethoxyethyl chloride is 100% according to gas phase detection. After the reaction is completed, the material is allowed to stand for separation to remove the water phase, and 136.2g of the organic phase is collected.

[0093] The above-obtained 136.2g of tert-octylphenoxyethoxyethyldimethylamine was added to a 1L four-necked reaction bottle, and 100.2g of methyl isobutyl ketone and 126.6g of benzyl chloride were added in sequence, the temperature was raised to reflux, the reaction was carried out for 2h, 168.2g of cyclohexane was slowly added, the temperature was lowered to crystallize, 156.3g of solid was collected, the filter cake was vacuum dried at -0.098MPa and 35°C, and then the filter cake was crushed to obtain the benzethonium chloride product. Finally, 142.6g of light yellow product was obtained, the total yield of two steps was 68.9%, the purity was 97.60%, the melting point of the product was 156.5-157.7°C, and the product did not meet the index of the United States Pharmacopoeia.

[0094] The above data confirm that the yield and content of existing synthesis technology are very low and fail to meet the requirements of the pharmacopoeia.

[0095] The present invention is not limited to the above-mentioned embodiments. On the basis of the technical solution disclosed in the present invention, technicians in this field can make some substitutions and deformations to some technical features therein according to the disclosed technical content without creative labor, and these substitutions and deformations are all within the protection scope of the present invention.

Claims

1. A method for preparing pharmaceutical grade benzethonium chloride, characterized in that, The reaction formula is as follows: S1: S2: ; S1-1: Preparation of compound 3 Add 4-tert-octylphenoxyethoxyethyl chloride 2, dimethylamine salt and catalyst into the reaction kettle under nitrogen protection, heat up for reaction, maintain for 2-5 hours, and end the reaction when the residual amount of 4-tert-octylphenoxyethoxyethyl chloride 2 is controlled to be ≤3.0%; after the reaction is completed by stirring the reactants, cool down to below 35°C, add ethyl acetate, and let the reaction solution stand to separate into organic layers; The catalyst is cuprous iodide and PdCl2(dppf); S1-2: Distillation and purification of crude product The organic layer was decompressed using an oil pump, the vacuum degree of the distillation system was controlled at 0.01-1.0 mbar, the oil bath temperature was 160-180°C, the speed of the scraper was 200-300 rpm, and molecular distillation was performed continuously to obtain compound 3; S2-1: Preparation of Compound 1 Pre-treatment of compound 3: Add compound 3 and solvent ethyl acetate into the reactor under nitrogen protection, stir and heat to 30-50°C, add activated carbon for decolorization for the specified time, pass through a precision filter with a pore size of less than 45 microns, filter to step S2-2 for reaction; S2-2: Preparation of Compound 1 Into the reactor, add the p-tert-octylphenoxyethoxyethyldimethylamine 3 solution of S2-1 under nitrogen protection, then draw in benzyl chloride through a precision filter, stir and heat to react, the reaction temperature is 40-60°C, the reaction is maintained until the process specified time, no sampling is required for central control, the reaction is terminated, the reaction liquid is filtered, the obtained solid is added with ethyl acetate, stirred and washed, and the obtained solid is dried under reduced pressure to obtain compound 1.

2. A method for preparing pharmaceutical grade benzethonium chloride according to claim 1, characterized in that, In the formula in step S1-1, the dimethylamine salt is dimethylamine hydrochloride, dimethylamine hydrobromide, dimethylamine sulfate, or dimethylamine hydroiodide.

3. A method for preparing pharmaceutical grade benzethonium chloride according to claim 2, characterized in that, In the formula in step S1-1, the dimethylamine salt is dimethylamine hydrochloride.

4. A method for preparing pharmaceutical grade benzethonium chloride according to claim 1, characterized in that, The absolute pressure during molecular distillation is 0.005MPa-0.01MPa.